RU2018114447A - Введение дейтерированных усилителей cftr - Google Patents
Введение дейтерированных усилителей cftr Download PDFInfo
- Publication number
- RU2018114447A RU2018114447A RU2018114447A RU2018114447A RU2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- compound
- paragraphs
- pharmaceutically acceptable
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Claims (18)
1. Способ лечения состояния, которое опосредовано CFTR, у пациента, включающий введение пациенту соединения, представленного следующей структурной формулой
или его фармацевтически приемлемой соли
в количестве от 50 мг до 200 мг, один раз в сутки.
2. Способ по п. 1, где состоянием является муковисцидоз.
3. Способ по любому из пп. 1-2, включающий введение пациенту 100 мг Соединения (I) или его фармацевтически приемлемой соли в сутки.
4. Способ по любому из пп. 1-3, где соединение вводят перорально.
5. Способ по п. 4, где соединение вводят в составе фармацевтической композиции, которая является таблеткой.
6. Способ по п. 4, где соединение вводят в составе фармацевтической композиции, которая является гранулами.
7. Способ по любому из пп. 1-6, где любой атом, не обозначенный как дейтерий в любом из вариантов осуществления изобретения, указанных выше, присутствует в его натуральной изотопной обогащенности.
8. Фармацевтическая композиция, включающая фармацевтически приемлемый носитель или разбавитель и от 50 мг до 200 мг соединения представленного следующей структурной формулой
или его фармацевтически приемлемой соли.
9. Фармацевтическая композиция по п. 8, включающая 100 мг соединения (I).
10. Фармацевтическая композиция по п. 8 или 9, где фармацевтическая композиция подходит для перорального введения.
11. Фармацевтическая композиция по п. 8 или 9, где композицией является таблетка.
12. Фармацевтическая композиция по п. 8 или 9, где композицией является гранула.
13. Фармацевтическая композиция по любому из пп. 8-12, где композицию вводят один раз в сутки.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221531P | 2015-09-21 | 2015-09-21 | |
| US62/221,531 | 2015-09-21 | ||
| US201562238511P | 2015-10-07 | 2015-10-07 | |
| US62/238,511 | 2015-10-07 | ||
| US201662348855P | 2016-06-10 | 2016-06-10 | |
| US62/348,855 | 2016-06-10 | ||
| PCT/US2016/052922 WO2017053455A1 (en) | 2015-09-21 | 2016-09-21 | Administration of deuterated cftr potentiators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018114447A true RU2018114447A (ru) | 2019-10-23 |
| RU2018114447A3 RU2018114447A3 (ru) | 2020-02-21 |
| RU2761344C2 RU2761344C2 (ru) | 2021-12-07 |
Family
ID=58387264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018114447A RU2761344C2 (ru) | 2015-09-21 | 2016-09-21 | Введение дейтерированных усилителей cftr |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180353500A1 (ru) |
| EP (2) | EP3352757B1 (ru) |
| JP (2) | JP6849686B2 (ru) |
| KR (1) | KR20180058745A (ru) |
| CN (1) | CN108367002A (ru) |
| AU (2) | AU2016326441B2 (ru) |
| BR (1) | BR112018005454A2 (ru) |
| CA (1) | CA2998911C (ru) |
| HK (1) | HK1258472A1 (ru) |
| IL (2) | IL257993A (ru) |
| MA (1) | MA42950A (ru) |
| MX (1) | MX2018003331A (ru) |
| RU (1) | RU2761344C2 (ru) |
| SG (1) | SG10201913588YA (ru) |
| UA (1) | UA124619C2 (ru) |
| WO (1) | WO2017053455A1 (ru) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
| US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
| EP3352758A4 (en) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals (Europe) Limited | Deuterated cftr potentiators |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IL277491B (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20200171015A1 (en) * | 2017-07-17 | 2020-06-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR20200096560A (ko) | 2017-12-01 | 2020-08-12 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막관통 조절 인자의 제조 방법 |
| MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| FI3880197T3 (fi) | 2018-11-14 | 2023-05-04 | Vertex Pharma | Menetelmiä kystisen fibroosin hoitamiseksi |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| FR3096890B1 (fr) | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| AU2020328568A1 (en) | 2019-08-14 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| FR3109524B1 (fr) | 2020-04-22 | 2022-04-08 | H4 Orphan Pharma | Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales. |
| FR3111071B1 (fr) | 2020-06-04 | 2023-01-13 | H4 Orphan Pharma | Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus. |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US20230303589A1 (en) | 2020-08-13 | 2023-09-28 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076621A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225763A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| BR112023006470A2 (pt) | 2020-10-07 | 2023-09-26 | Vertex Pharma | Moduladores de regulador de condutância transmembrana de fibrose cística |
| PE20231108A1 (es) | 2020-10-07 | 2023-07-19 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
| AU2021358063A1 (en) | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CZ20033211A3 (cs) | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
| AU2005292339A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| AU2011255237A1 (en) * | 2010-05-20 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| HUE047354T2 (hu) * | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| MX349159B (es) * | 2011-05-18 | 2017-07-14 | Concert Pharmaceuticals Inc | Derivados deuterados de ivacaftor. |
| WO2013130669A1 (en) | 2012-02-27 | 2013-09-06 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| MY183582A (en) * | 2012-11-19 | 2021-02-26 | Vertex Pharmaceuticals Europe Ltd | Deuterated cftr potentiators |
| CN109364075B (zh) * | 2012-11-21 | 2021-10-29 | 顶点制药（欧洲）有限公司 | 氘化cftr增效剂 |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
-
2016
- 2016-09-21 CN CN201680067707.1A patent/CN108367002A/zh active Pending
- 2016-09-21 JP JP2018534496A patent/JP6849686B2/ja active Active
- 2016-09-21 SG SG10201913588YA patent/SG10201913588YA/en unknown
- 2016-09-21 BR BR112018005454A patent/BR112018005454A2/pt not_active Application Discontinuation
- 2016-09-21 WO PCT/US2016/052922 patent/WO2017053455A1/en active Application Filing
- 2016-09-21 MA MA042950A patent/MA42950A/fr unknown
- 2016-09-21 RU RU2018114447A patent/RU2761344C2/ru active
- 2016-09-21 EP EP16849524.0A patent/EP3352757B1/en active Active
- 2016-09-21 AU AU2016326441A patent/AU2016326441B2/en active Active
- 2016-09-21 MX MX2018003331A patent/MX2018003331A/es unknown
- 2016-09-21 US US15/761,532 patent/US20180353500A1/en not_active Abandoned
- 2016-09-21 EP EP23191452.4A patent/EP4292588A3/en active Pending
- 2016-09-21 KR KR1020187010964A patent/KR20180058745A/ko not_active Application Discontinuation
- 2016-09-21 UA UAA201804280A patent/UA124619C2/uk unknown
- 2016-09-21 CA CA2998911A patent/CA2998911C/en active Active
-
2018
- 2018-03-08 IL IL257993A patent/IL257993A/en unknown
-
2019
- 2019-01-17 HK HK19100788.5A patent/HK1258472A1/zh unknown
-
2020
- 2020-05-14 US US15/931,944 patent/US20200375973A1/en active Pending
-
2021
- 2021-03-04 JP JP2021034591A patent/JP7196217B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201135A patent/AU2022201135B2/en active Active
- 2022-03-20 IL IL291517A patent/IL291517A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017053455A1 (en) | 2017-03-30 |
| EP3352757A1 (en) | 2018-08-01 |
| JP2018534348A (ja) | 2018-11-22 |
| IL257993A (en) | 2018-05-31 |
| EP3352757A4 (en) | 2018-08-01 |
| UA124619C2 (uk) | 2021-10-20 |
| EP4292588A2 (en) | 2023-12-20 |
| CN108367002A (zh) | 2018-08-03 |
| RU2761344C2 (ru) | 2021-12-07 |
| AU2016326441B2 (en) | 2021-11-25 |
| BR112018005454A2 (pt) | 2018-10-09 |
| MA42950A (fr) | 2018-08-01 |
| AU2022201135B2 (en) | 2024-03-28 |
| EP3352757B1 (en) | 2023-08-16 |
| IL291517A (en) | 2022-05-01 |
| MX2018003331A (es) | 2018-08-16 |
| JP7196217B2 (ja) | 2022-12-26 |
| US20200375973A1 (en) | 2020-12-03 |
| SG10201913588YA (en) | 2020-02-27 |
| KR20180058745A (ko) | 2018-06-01 |
| JP2021091723A (ja) | 2021-06-17 |
| AU2016326441A1 (en) | 2018-04-19 |
| CA2998911A1 (en) | 2017-03-30 |
| AU2022201135A1 (en) | 2022-03-17 |
| HK1258472A1 (zh) | 2019-11-15 |
| RU2018114447A3 (ru) | 2020-02-21 |
| EP4292588A3 (en) | 2024-02-28 |
| JP6849686B2 (ja) | 2021-03-24 |
| EP3352757C0 (en) | 2023-08-16 |
| CA2998911C (en) | 2023-05-23 |
| US20180353500A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2018534348A5 (ru) | ||
| JP2013505205A5 (ru) | ||
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2012193216A5 (ru) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA202090573A1 (ru) | Составы нирапариба | |
| JP2016511753A5 (ru) | ||
| JP2015510916A5 (ru) | ||
| CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
| JP2016510326A5 (ru) | ||
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| UA122336C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
| MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
| MX2018003890A (es) | Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine). | |
| JP2016514142A5 (ru) | ||
| RU2018119120A (ru) | D-пролиновые производные в качестве агента, уменьшающего количество sap |